DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...

Additionally, the ongoing appeal with Mylan regarding patent infringement ... Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops ...

In a report released today, Balaji Prasad from Barclays maintained a Sell rating on Viatris (VTRS – Research Report), with a price target ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

Natco Pharma announced that its partner, Mylan Pharmaceuticals, reached a settlement with Novo Nordisk in the ongoing U.S. patent litigation related to generic Ozempic (Semaglutide). The terms of ...

South Korea’s reputable yet increasingly taxed healthcare industry depends on a robust pharmaceutical sector. As domestic and international demand has increased, the country has further proven ...

Mallinckrodt Pharmaceuticals, Mylan Pharmaceutical AG and Medtronic Sandoz is involved in research and development efforts related to endocrine disorders, including adrenal insufficiency. The company ...

SAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. BioMarin ...

US pharma company Gilead Sciences is seeking regulatory ... including Dr. Reddy’s, Emcure, and Mylan, to produce and sell generic versions of lenacapavir in 120 resource-limited countries., ...

AEP GmbH was the victim of a targeted cyber attack on October 28, which led to the partial encryption of the company's IT systems. The company's own security systems detected the attack. The ...